Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside

Flavio Airoldi, Carlo Briguori, Domenico Cianflone, John Cosgrave, Goran Stankovic, Cosmo Godino, Mauro Carlino, Alaide Chieffo, Matteo Montorfano, Marco Mussardo, Iassen Michev, Antonio Colombo, Attilio Maseri

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Nitroprusside (NTP) is used for the treatment of slow coronary flow (SCF) after coronary interventions. The wide variation in dosage, route, and timing of its administration in the reported studies prevents an objective assessment of its efficacy. We report the incidence and response to a standardized NTP protocol of SCF after successful stent implantation. Selective intracoronary administration of incremental doses (initial bolus of 80 μg incremented by 40 μg) of NPT was assessed in 21 patients who developed SCF in a series of 2,212 consecutive patients who underwent successful stent placement from January to October 2005. SCF was observed only in patients treated for acute myocardial infarction (AMI; 11.5%, 12 of 105) or saphenous vein graft (SVG) stenosis (8.2%, 9 of 109). An intracoronary bolus of nitroglycerin did not restore normal Thrombolysis In Myocardial Infarction (TIMI) flow in any patient. The first 80-μg dose of NTP restored normal TIMI flow in 58% of patients (7 of 12) with AMI and in 44% of patients (4 of 9)with SVG stenosis. The maximal dose (120/160 μg) restored normal TIMI flow in all remaining patients with AMI but in only 1 additional patient with SVG stenosis. At the end of the procedure, the percent decrease in corrected TIMI frame count was significantly larger in patients with AMI (-44 ± 10%) than in those with SVG stenosis (-24 ± 16%, p = 0.02). In a large consecutive series of successful stent procedures, SCF was found only in patients with ST-elevation AMI (11.5%) or with a stenosed SVG (8.2%). In conclusion, the standardized protocol of intracoronary NTP administration succeeded in normalizing SCF in all patients with AMI but in only 5 of 9 patients with SVG stenosis. This latter subgroup requires other therapeutic strategies.

Original languageEnglish
Pages (from-to)916-920
Number of pages5
JournalThe American Journal of Cardiology
Volume99
Issue number7
DOIs
Publication statusPublished - Apr 1 2007

Fingerprint

Nitroprusside
Stents
Saphenous Vein
Pathologic Constriction
Transplants
Myocardial Infarction
Nitroglycerin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside. / Airoldi, Flavio; Briguori, Carlo; Cianflone, Domenico; Cosgrave, John; Stankovic, Goran; Godino, Cosmo; Carlino, Mauro; Chieffo, Alaide; Montorfano, Matteo; Mussardo, Marco; Michev, Iassen; Colombo, Antonio; Maseri, Attilio.

In: The American Journal of Cardiology, Vol. 99, No. 7, 01.04.2007, p. 916-920.

Research output: Contribution to journalArticle

Airoldi, Flavio ; Briguori, Carlo ; Cianflone, Domenico ; Cosgrave, John ; Stankovic, Goran ; Godino, Cosmo ; Carlino, Mauro ; Chieffo, Alaide ; Montorfano, Matteo ; Mussardo, Marco ; Michev, Iassen ; Colombo, Antonio ; Maseri, Attilio. / Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside. In: The American Journal of Cardiology. 2007 ; Vol. 99, No. 7. pp. 916-920.
@article{74e912c61eb34ae0a2a29a27be203a78,
title = "Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside",
abstract = "Nitroprusside (NTP) is used for the treatment of slow coronary flow (SCF) after coronary interventions. The wide variation in dosage, route, and timing of its administration in the reported studies prevents an objective assessment of its efficacy. We report the incidence and response to a standardized NTP protocol of SCF after successful stent implantation. Selective intracoronary administration of incremental doses (initial bolus of 80 μg incremented by 40 μg) of NPT was assessed in 21 patients who developed SCF in a series of 2,212 consecutive patients who underwent successful stent placement from January to October 2005. SCF was observed only in patients treated for acute myocardial infarction (AMI; 11.5{\%}, 12 of 105) or saphenous vein graft (SVG) stenosis (8.2{\%}, 9 of 109). An intracoronary bolus of nitroglycerin did not restore normal Thrombolysis In Myocardial Infarction (TIMI) flow in any patient. The first 80-μg dose of NTP restored normal TIMI flow in 58{\%} of patients (7 of 12) with AMI and in 44{\%} of patients (4 of 9)with SVG stenosis. The maximal dose (120/160 μg) restored normal TIMI flow in all remaining patients with AMI but in only 1 additional patient with SVG stenosis. At the end of the procedure, the percent decrease in corrected TIMI frame count was significantly larger in patients with AMI (-44 ± 10{\%}) than in those with SVG stenosis (-24 ± 16{\%}, p = 0.02). In a large consecutive series of successful stent procedures, SCF was found only in patients with ST-elevation AMI (11.5{\%}) or with a stenosed SVG (8.2{\%}). In conclusion, the standardized protocol of intracoronary NTP administration succeeded in normalizing SCF in all patients with AMI but in only 5 of 9 patients with SVG stenosis. This latter subgroup requires other therapeutic strategies.",
author = "Flavio Airoldi and Carlo Briguori and Domenico Cianflone and John Cosgrave and Goran Stankovic and Cosmo Godino and Mauro Carlino and Alaide Chieffo and Matteo Montorfano and Marco Mussardo and Iassen Michev and Antonio Colombo and Attilio Maseri",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.amjcard.2006.10.057",
language = "English",
volume = "99",
pages = "916--920",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside

AU - Airoldi, Flavio

AU - Briguori, Carlo

AU - Cianflone, Domenico

AU - Cosgrave, John

AU - Stankovic, Goran

AU - Godino, Cosmo

AU - Carlino, Mauro

AU - Chieffo, Alaide

AU - Montorfano, Matteo

AU - Mussardo, Marco

AU - Michev, Iassen

AU - Colombo, Antonio

AU - Maseri, Attilio

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Nitroprusside (NTP) is used for the treatment of slow coronary flow (SCF) after coronary interventions. The wide variation in dosage, route, and timing of its administration in the reported studies prevents an objective assessment of its efficacy. We report the incidence and response to a standardized NTP protocol of SCF after successful stent implantation. Selective intracoronary administration of incremental doses (initial bolus of 80 μg incremented by 40 μg) of NPT was assessed in 21 patients who developed SCF in a series of 2,212 consecutive patients who underwent successful stent placement from January to October 2005. SCF was observed only in patients treated for acute myocardial infarction (AMI; 11.5%, 12 of 105) or saphenous vein graft (SVG) stenosis (8.2%, 9 of 109). An intracoronary bolus of nitroglycerin did not restore normal Thrombolysis In Myocardial Infarction (TIMI) flow in any patient. The first 80-μg dose of NTP restored normal TIMI flow in 58% of patients (7 of 12) with AMI and in 44% of patients (4 of 9)with SVG stenosis. The maximal dose (120/160 μg) restored normal TIMI flow in all remaining patients with AMI but in only 1 additional patient with SVG stenosis. At the end of the procedure, the percent decrease in corrected TIMI frame count was significantly larger in patients with AMI (-44 ± 10%) than in those with SVG stenosis (-24 ± 16%, p = 0.02). In a large consecutive series of successful stent procedures, SCF was found only in patients with ST-elevation AMI (11.5%) or with a stenosed SVG (8.2%). In conclusion, the standardized protocol of intracoronary NTP administration succeeded in normalizing SCF in all patients with AMI but in only 5 of 9 patients with SVG stenosis. This latter subgroup requires other therapeutic strategies.

AB - Nitroprusside (NTP) is used for the treatment of slow coronary flow (SCF) after coronary interventions. The wide variation in dosage, route, and timing of its administration in the reported studies prevents an objective assessment of its efficacy. We report the incidence and response to a standardized NTP protocol of SCF after successful stent implantation. Selective intracoronary administration of incremental doses (initial bolus of 80 μg incremented by 40 μg) of NPT was assessed in 21 patients who developed SCF in a series of 2,212 consecutive patients who underwent successful stent placement from January to October 2005. SCF was observed only in patients treated for acute myocardial infarction (AMI; 11.5%, 12 of 105) or saphenous vein graft (SVG) stenosis (8.2%, 9 of 109). An intracoronary bolus of nitroglycerin did not restore normal Thrombolysis In Myocardial Infarction (TIMI) flow in any patient. The first 80-μg dose of NTP restored normal TIMI flow in 58% of patients (7 of 12) with AMI and in 44% of patients (4 of 9)with SVG stenosis. The maximal dose (120/160 μg) restored normal TIMI flow in all remaining patients with AMI but in only 1 additional patient with SVG stenosis. At the end of the procedure, the percent decrease in corrected TIMI frame count was significantly larger in patients with AMI (-44 ± 10%) than in those with SVG stenosis (-24 ± 16%, p = 0.02). In a large consecutive series of successful stent procedures, SCF was found only in patients with ST-elevation AMI (11.5%) or with a stenosed SVG (8.2%). In conclusion, the standardized protocol of intracoronary NTP administration succeeded in normalizing SCF in all patients with AMI but in only 5 of 9 patients with SVG stenosis. This latter subgroup requires other therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=33947628754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947628754&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.10.057

DO - 10.1016/j.amjcard.2006.10.057

M3 - Article

VL - 99

SP - 916

EP - 920

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -